Explore our extensive collection of validation studies, demonstrating InBody BWA’s commitment to precision and reliability in body composition analysis.
At InBody BWA, ensuring the accuracy and reliability of our technology is a top priority. Our validation studies demonstrate our commitment to precision in body composition analysis, offering trusted data that supports clinicians and researchers in making informed decisions. Explore our extensive collection of studies to see how InBody technology stands up to rigorous scientific evaluation.
This study validates InBody’s measurements with deuterium dilution, showcasing its accuracy in measuring body water content. The findings underscore its reliability in multi-ethnic populations, enhancing its clinical applicability.
Read ❯
This study highlights InBody’s superior precision in body composition measurement compared to traditional methods. With validation against DXA, the results demonstrate a high level of agreement and reliability across various demographics.
Read ❯
This study positions InBody as a dependable alternative to computed tomography (CT) for body composition analysis. It emphasizes the technology’s ability to deliver precise measurements without the need for radiation.
Read ❯
A July 2022 evaluation of the InBody 970 and BWA 2.0 devices revealed high correlations with dual-energy X-ray absorptiometry (DEXA) results, confirming their precision in measuring appendicular lean mass, fat-free mass, and body fat percentage.
Read ❯
Published in 2022, a study compared the InBody 770 against body composition gold standards (DXA and ADP) with 110 participants and found it provided highly valid measurements of body fat percentage and fat-free mass, applicable across diverse ethnic backgrounds.
Read ❯
A 2020 study in the Journal of Pediatric Gastroenterology and Nutrition highlighted that InBody devices were reasonably accurate for estimating body fat in children with obesity, serving as a cost-effective alternative to DXA.
Read ❯
A study with 109 multi-ethnic participants looked at comparisons between bioelectrical impedance spectroscopy (BIS) devices, including the InBody (IB) 770, and deuterium dilution for measures of total body water (TBW). For baseline measures of TBW, each participant provided a saliva sample and completed BIS and IB measurements of TBW, followed by ingestion of deuterium oxide (D2O). Participants were asked to provide a second saliva sample for TBW analysis after a period of equilibration. Researchers found that “IB estimates were excellent to very good (TE = 1.95 L, R2 = 0.975)”. They further stated that “Validity results did not vary meaningfully between race and ethnicity.”
In a 2023 study published by Scientific Reports assessing the effects of interactions between visceral adiposity, obesity, and sarcopenia on NAFLD, the accuracy of the InBody 720 was compared against computed tomography (CT) in 1,927 subjects. The authors found a “significant strong correlation between measurements with the InBody 720 and those measured with CT (ASM, r=0.898, P<0.001 and VFA, r=0.714, P<0.001)”. The study concluded that positive associations, and additive interaction effects, were shown between NAFLD and sarcopenia, obesity, and visceral adiposity.
Now with more frequencies, and frequencies up to 3000 kHz, the InBody970 and the BWA 2.0 devices provide not only more outputs, but greater precision. Life journal in a July 2022 publication evaluated the newest InBody devices compared to dual-energy X-ray absorptiometry (DEXA) in a cohort of 109 individuals. What they found was that high-frequency InBody devices showed a “high correlation with the DEXA results” for assessing appendicular lean mass (β ≥ 0.95), fat-free mass (R2 ≥ 0.95), and percent body fat (R2≥ 0.89).
The Journal of Pediatric Gastroenterology and Nutrition published a 2020 study that evaluated the accuracy of different BIA devices relative to DXA in children with obesity. Amongst other BIA, InBody stood out as it was “relatively accurate for estimating body fat percentage” and was not limited to patients younger than 10 or patients with high body fat percentage (>50%). Beyond being a “reasonably accurate alternative to DXA” in pediatric obesity, InBody is available at a tenth of the cost.
Ready to move beyond the foundational validation studies and delve into the science? Deepen your understanding of Body Composition principles and explore how accurate Body Composition Analysis is applied in clinical settings, academia, and professional practice.